630421-42-0

Basic information

• Product Name: CYCLOPROPANESULFONIC ACID TERT-BUTYLAMIDE
• Synonyms: CYCLOPROPANESULFONAMIDE, N-(1,1-DIMETHYLETHYL)-;CYCLOPROPANESULFONIC ACID TERT-BUTYLAMIDE;N-TERT-BUTYLCYCLOPROPANESULFONAMIDE;N-(1,1-dimethylethyl)cyclopropanesulfonAmide
• CAS NO: 630421-42-0
• Molecular Formula: C7H15NO2S
• Molecular Weight: 177.266
• Mol File: 630421-42-0.mol

Chemical Properties

• Melting Point: 81-83℃
• Boiling Point: 255℃
• Flash Point: 108℃
• Appearance: /
• Density: 1.14
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.88±0.20(Predicted)
• CAS DataBase Reference: CYCLOPROPANESULFONIC ACID TERT-BUTYLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOPROPANESULFONIC ACID TERT-BUTYLAMIDE(630421-42-0)
• EPA Substance Registry System: CYCLOPROPANESULFONIC ACID TERT-BUTYLAMIDE(630421-42-0)

Safety Data

• Hazardous Substances Data: 630421-42-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
CYCLOPROPANESULFONIC ACID TERT-BUTYLAMIDE is used as a strong, non-nucleophilic base and catalyst for facilitating various types of organic reactions. Its ability to selectively deprotonate less acidic protons is particularly valuable in the synthesis of complex organic molecules, enhancing the efficiency and selectivity of the reactions.
Used in Aldol Reactions:
In the Aldol Reaction industry, CYCLOPROPANESULFONIC ACID TERT-BUTYLAMIDE is used as a catalyst to promote the formation of β-hydroxy aldehydes or ketones from aldehydes or ketones and a nucleophile. Its selectivity in deprotonating less acidic protons ensures the desired product formation with minimal side reactions.
Used in Michael Additions:
In the Michael Additions industry, CYCLOPROPANESULFONIC ACID TERT-BUTYLAMIDE is utilized as a catalyst to facilitate the addition of a nucleophile to an α,β-unsaturated carbonyl compound. Its strong basicity and selectivity in deprotonating less acidic protons make it an effective reagent for this type of reaction.
Used in Wittig Reactions:
In the Wittig Reactions industry, CYCLOPROPANESULFONIC ACID TERT-BUTYLAMIDE is employed as a catalyst to promote the conversion of aldehydes or ketones into alkenes through the formation of a phosphorane intermediate. Its unique properties contribute to the efficiency and selectivity of the Wittig reaction, making it a valuable reagent in the synthesis of alkenes.

Upstream product

• 154350-29-5 cyclopropanesulphonamide 
• 84379-72-6 1,3-dioxoisoindolin-2-yl 3,3-dimethylbutanoate 
• 691-64-5 di-tert-butyl oxalate 
• 139631-62-2 cyclopropanesulfonyl chloride 
• 75-64-9 tert-butylamine 
• 1633-82-5 3-chloro-n-propanesulfonyl chloride 
• 63132-85-4 N-tert-butyl-(3-chloro)propylsulfonamide 

Downstream Products

• 681808-55-9 N-tert-butyl-1-ethyl-cyclopropanesulfonamide 
• 669008-25-7 N-(tert-butyl)-1-methylcyclopropane-1-sulfonamide 

Relevant articles and documents

P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: Discovery of MK-2748 and MK-6325

With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clinically relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK-5172. Quinazolinone-containing macrocycles were identified as promising leads, and optimization for superior cross-genotype and mutant enzyme potency as well as rat liver and plasma concentrations following oral dosing, led to the development of MK-2748. Additional investigation of a series of bis-macrocycles containing a fused 18- and 15-membered ring system were also optimized for the same properties, leading to the discovery of MK-6325. Both compounds display the broad genotype and mutant potency necessary for clinical development as next-generation HCV NS3/4a protease inhibitors.

Organophotoredox-Catalyzed Decarboxylative N-Alkylation of Sulfonamides

We developed an organophotoredox-catalyzed reaction for N-alkylation of sulfonamides with aliphatic carboxylic acid-derived redox active esters as alkylating reagents. Under mild and transition metal-free conditions, a series of functionalized N-alkylated sulfonamides were prepared. This protocol also enabled the functionalization of pharmaceutical drugs bearing a sulfonamide or carboxylic acid moiety. This radical-mediated process allowed the assembly of three components including sulfonamides, redox active esters, and alkenes to yield complex sulfonamides in a one-pot manner.

Zn- And Cu-catalyzed coupling of tertiary alkyl bromides and oxalates to forge challenging C?O, C?S, and C?N bonds

We describe here the facile construction of sterically hindered tertiary alkyl ethers and thioethers via the Zn(OTf)2catalyzed coupling of alcohols/phenols with unactivated tertiary alkyl bromides and the Cu(OTf)2-catalyzed thiolation of unactivated tertiary alkyl oxalates with thiols. The present protocol represents one of the most effective unactivated tertiary C(sp3)? heteroatom bond-forming conditions via readily accessible Lewis acid catalysis that is surprisingly less developed.

ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Toward the Synthesis of Fluorinated Analogues of HCV NS3/4A Serine Protease Inhibitors Using Methyl α-Amino-β-fluoro-β-vinylcyclopropanecarboxylate as Key Intermediate

Synthesis of fluorocyclopropyl building blocks, which constitute the core of various therapeutic agents against the hepatitis C virus, is described. The relevant methyl α-amino-β-fluoro-β-vinylcyclopropanecarboxylate has been used as a key intermediate for the total synthesis of a fluorinated analogue of Simeprevir (TMC 435), a HCV NS3/4A protease inhibitor.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

HCV NS3 PROTEASE INHIBITORS

The present invention relates to macro-cyclic compounds of formula I that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections

Preparation of cyclopropyl sulfonylamides

A novel process for the preparation of cyclopropyl sulfonamide of the formula I is described. Cyclopropyl sulfonamide is a versatile building block for many biologically active compounds.

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.